The enzyme used in the manufacture of the strips GlucoQuick Diamond FAD-GDH is glucose dehydrogenase, the enzyme is recommended by the U.S. FDA because it ensures more accurate results, to eliminate the interference of oxygen variation versus exposure strip the environment and to not interfere with the test result of glucose with other non-glucose sugar as maltose and galactose.
The presentation in individual packaging strips GlucoQuick - Diamond ™ GDH-FAD enables high efficiency and low wastage rate retail strips risk of contamination (the strip has little exposure to oxygen and other environmental contaminants factors that may alter the effectiveness of the strip during handling prior to testing), this means greater economy (lower cost). Traditional packaging for other traditional test strip vial is including multiple strips (typically with 25 strips per bottle) subjecting the strips to oxygen exposure and increasing humidity and environmental pollutants which may diminish the effectiveness strip.
For Hospitals and point of care, GlucoQuick - Diamond ™ GDH-FAD is the best alternative for testing blood glucose, since the individual packaging ensures reliable results in all strips including use until real expiry date, with less waste useless strips contributing to a more effective and efficient management of inventory with better control of spending. Additionally health professionals involved in making the test may experience a higher level of biosecurity.
GlucoQuick Strips - Diamond ™ GDH-FAD are available for sale in individual packaging:
GlucoQuick test strips - Diamond ™ GDH-FAD are manufactured to Procaps - DIABETRICS by FORA Care Suisse AG.
For more information and product availability, please contact:
free online 018000522277
Started in 1977 as a family owned business pioneering in softgel contract manufacturing in Latin America, today Procaps Group has evolved to a dynamic and innovative corporation with over 3,000 employees who develop, manufacture and promote pharmaceutical products, veterinary, nutritional supplements, and cosmetics, as well as promotion and distribution of licensed products such as implants and prosthesis.
The corporation has a unique strength for marketing branded generic products supported by the fact of being among the top companies generating drug prescriptions in most countries. Its product portfolio covers more than twelve therapeutic areas in which it offers excellent products for critical and chronic diseases, powered by individual sales forces reaching 100% of all specialists within these therapeutic areas and nearly all key opinion leaders.
Procaps Group has well established operations and a trained sales force in the Andean Region (Colombia, Venezuela, Peru, Ecuador, Bolivia) and all over Central America and the Caribbean. Moreover, the Corporation has been active in the international market for more than 30 years reaching over 300 clients worldwide with its business-to-business operation.
By reaching 10 countries in Latin America with branded products for specialists and hospital use, as well as exporting to more than 35 countries worldwide through value added development and supply services, Procaps Group will have projected sales of US$ 400 MM in year 2013. In the near future, the Group will be present in the US Rx market thanks to strategic alliances with US companies and several products already under registration with US-FDA.
Different production sites throughout Latin America enables the Corporation to develop
and manufacture most pharmaceutical forms like powders, tablets, liquids, sterile solutions, hormonal products..
Our branded pharmaceutical products are commercialized in:
Latin America: Colombia – Venezuela - Peru - Ecuador- Bolivia - Dominican Republic - Guatemala – Panama - El Salvador.
Opening countries: Costa Rica - Nicaragua – Honduras.
In Colombia, we have 2,200 employees, among them a sales force of 300
In the other countries, there are a total of 850 employees, and 650 Med Reps.
Besides manufacturing, we have three commercialization Divisions: FARMA, (Prescription Drugs), VITAL CARE (OTC Drugs), HOSPITALARIA (Institutional and Tender commercialization) and DIABETRICS
Our portfolio includes some of the most interesting anti-diabetics, antibiotics, non-steroidal anti-inflammatory drugs, analgesics, dermatologic drugs, antimycotics, erectile dysfunction, anti-protozoal agents, anti-helmintic agents, cough medicines, drugs for central nervous system illnesses, antiallergics, cardiovascular, gastrointestinal and ophthalmologic drugs, vitamins and natural products. Our pipeline also includes drugs against cancer.
We are also expanding our product portfolio with innovative drugs in biotechnology.
For more information, visit: http://www.procapslaboratorios.com